Pages that link to "Q44865794"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG). (Q44865794):
Displaying 22 items.
- Combined oral contraceptive pills for treatment of acne (Q24240056) (← links)
- Combined oral contraceptive pills for treatment of acne (Q24246230) (← links)
- (Q28203848) (← links)
- Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology (Q34588375) (← links)
- Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women (Q36107595) (← links)
- Low-dose ethinylestradiol/levonorgestrel (Q36304799) (← links)
- Efficacy of contraceptive methods: A review of the literature (Q37688124) (← links)
- Contraception and headache (Q38083769) (← links)
- Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. (Q38485932) (← links)
- Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies (Q42688053) (← links)
- Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study (Q43103057) (← links)
- Yasminelle((R)): a new low-dose combined oral contraceptive containing drospirenone (Q43267039) (← links)
- A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment (Q43726031) (← links)
- Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone (Q43727654) (← links)
- Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials (Q43774214) (← links)
- A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control (Q43774215) (← links)
- Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel (Q44071332) (← links)
- Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women. (Q52879856) (← links)
- Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis. (Q52894307) (← links)
- Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20??g and Drospirenone 3mg (Q61896522) (← links)
- Oral contraception and cardiovascular risk factors during adolescence (Q73314410) (← links)
- Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use (Q83644767) (← links)